^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
pacmilimab (CX-072)
i
Other names: CX-072, CX 072, probody CX-072, PD-L1 probody therapeutic CX-072
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CytomX
Drug class:
PD-L1 inhibitor
Related drugs:
11ms
CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=125, Completed, CytomX Therapeutics | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
almost2years
CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=125, Active, not recruiting, CytomX Therapeutics | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Apr 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over2years
CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=125, Active, not recruiting, CytomX Therapeutics | Recruiting --> Active, not recruiting | N=200 --> 125
Enrollment closed • Enrollment change • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over2years
CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, CytomX Therapeutics | N=150 --> 200 | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
3years
Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab (SABCS 2021)
This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with praluzatamab ravtansine as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
Clinical • P2 data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 amplification • PD-L1 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over3years
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. (PubMed, J Immunother Cancer)
Pacmilimab can be administered safely at the RP2D of 10 mg/kg every 14 days. At this dose, pacmilimab had a low rate of immune-mediated toxicity and showed signs of antitumor activity in patients not selected for high PD-L1 expression.
Clinical • P1 data • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • TMB-H • PD-L1 overexpression
|
pacmilimab (CX-072)
over3years
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. (PubMed, J Immunother Cancer)
The MTD and recommended phase 2 dose of pacmilimab (10 mg/kg)+ipilimumab (3 mg/kg) every 3 weeks is active and has a favorable tolerability profile.
Clinical • P1 data • Journal • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Yervoy (ipilimumab) • pacmilimab (CX-072)
almost4years
[VIRTUAL] Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) (ESMO-BC 2021)
This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with CX-2009 as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
Clinical • P2 data • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • PD-L1 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
almost4years
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=150, Recruiting, CytomX Therapeutics | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
4years
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
P2, N=150, Not yet recruiting, CytomX Therapeutics
Clinical • New P2 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
4years
[VIRTUAL] A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX‑2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC) (SABCS 2020)
This trial is actively enrolling. Email address for questions or comments: gpaton@cytomx.com
Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • PD-L1 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over4years
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over4years
[VIRTUAL] CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). (ASCO 2020)
CX-2009 at 7 mpk is the RP2D on Q3W schedule. Phase II expansion has begun in pts with HR+/HER2- BC. The Q2W schedule will continue to enroll pts to define the RP2D.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
over4years
[VIRTUAL] PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. (ASCO 2020)
CX-072 monotherapy demonstrated durable responses consistent with activation of the PROBODY therapeutic in the TME. The safety profile supports the tolerability of CX-072 as monotherapy and when combined with IPI3. CX-072 + IPI3 demonstrated activity in heavily pretreated pts with various tumors.
Clinical • Combination therapy
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Yervoy (ipilimumab) • pacmilimab (CX-072)
Share via
